Regeneron Pharmaceuticals (REGN) EBITDA Margin (2009 - 2026)

Regeneron Pharmaceuticals has reported EBITDA Margin for 18 years, with the latest figure at 30.15% in Q2 2026.

• On a quarterly basis, EBITDA Margin rose 78.0% year-over-year to 30.15% in Q2 2026; TTM through Jun 2026 was 24.74%, a 228.0% decrease from a year earlier, with the FY2025 full-year figure at 24.95%, down 315.0% from the prior year.
• EBITDA Margin was 30.15% for Q2 2026 at Regeneron Pharmaceuticals, up from 17.83% in the prior quarter.
• The five-year high for EBITDA Margin was 1146.8% in Q4 2022, with the low at 17.83% in Q1 2026.
• Average EBITDA Margin over 5 years is 91.78%, with a median of 30.04% recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin jumped 109349 bps in 2022, then tumbled 111847 bps in 2023.
• Over 5 years, EBITDA Margin stood at 1146.8% in 2022, then tumbled by 98 bps to 28.33% in 2023, then dropped by 8 bps to 26.13% in 2024, then slipped by 13 bps to 22.65% in 2025, then jumped by 33 bps to 30.15% in 2026.
• The last three EBITDA Margin figures came in at 30.15% (Q2 2026), 17.83% (Q1 2026), and 22.65% (Q4 2025), per Business Quant data.